2017. VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN. International Journal of Pharmaceutical Sciences and Drug Research. 9, 5 (Sep. 2017), 224–227. DOI:https://doi.org/10.25004/IJPSDR.2017.090504.